Skip to content
The Policy VaultThe Policy Vault

Opzelura (ruxolitinib) — Blue Cross Blue Shield of New Mexico

Contraindicated as concomitant therapy with IL-1 inhibitors

Initial criteria

  • Do NOT use any listed agents concurrently with IL-1 inhibitors.